Back
Cardiorenal syndrome (CRS) is a complex condition characterized by the coexistence of cardiac and renal dysfunction, which contributes to increased morbidity, mortality, and hospitalizations in individuals with heart failure (HF) and escalates healthcare costs. This study aims to ascertain the prevalence of CRS in patients undergoing follow-up at a Heart Failure Unit (HF-U), describe this patient population, compare it to individuals without CRS, and explore the variables associated with mortality and the need for chronic dialysis
This was an observational, descriptive, retrospective, cross-sectional study conducted on patients receiving care at the Multidisciplinary Heart Failure Unit (HF-U) between 2010 and 2021. Inclusion criteria comprised patients over 18 years of age, confirmed HF with reduced left ventricular ejection fraction (LVEFr) determined by echocardiography, and at least 12 months of follow-up. Patients with manifestations of renal disease during HF decompensation were excluded. Chronic kidney disease (CKD) and its stages were defined following KDIGO guidelines, and the estimated glomerular filtration rate (eGFR) was calculated using the CKD-EPI equation. The project obtained ethical committee approval. For analysis, two groups were considered: a study group with CRS (comprising patients with CKD and HF with LVEFr) and a control group without CRS (comprising patients with HF with LVEFr but without CKD).
A total of 501 patients were included in the study, with a CRS prevalence of 38.1%. Patients with CRS exhibited a higher median age (p<0.001), a greater prevalence of arterial hypertension (p=0.005) and diabetes (p=0.015), a more severe dyspnea functional class (p<0.001), lower hemoglobin levels (p<0.001), and increased mortality (p<0.001) in comparison to the control group (Table 1).
CRS was prevalent among patients with HF and reduced LVEFr. In comparison to the control group, patients with CRS were older, had more comorbidities, a lower prevalence of renin-angiotensin-aldosterone system blockade, and higher mortality rates. It is necessary to plan specific evaluation and treatment strategies for this group of patients.